Free tool
FAERS Monitor: Barhemsys
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209510 or its brand name (Barhemsys, Amisulpride). Reports on generic versions are filed under their own applications.
Reports
6,123
Serious
6,004
98% of reports
Hospitalization
3,019
Death reported
796
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective872
- drug interaction483
- weight increased446
- toxicity to various agents416
- neutropenia408
- schizophrenia339
- off label use333
- leukopenia316
- akathisia307
- extrapyramidal disorder302
- electrocardiogram qt prolonged283
- suicide attempt282
- somnolence280
- drug abuse261
- confusional state247
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 32 |
| 2005 | 49 |
| 2006 | 65 |
| 2007 | 79 |
| 2008 | 75 |
| 2009 | 111 |
| 2010 | 162 |
| 2011 | 189 |
| 2012 | 194 |
| 2013 | 229 |
| 2014 | 224 |
| 2015 | 223 |
| 2016 | 216 |
| 2017 | 287 |
| 2018 | 376 |
| 2019 | 451 |
| 2020 | 379 |
| 2021 | 397 |
| 2022 | 481 |
| 2023 | 469 |
| 2024 | 635 |
| 2025 | 467 |
| 2026 | 331 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,036 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| schizophreniaSignal | 339 | 98.6 | 88.7 | 31,747 |
| akathisiaSignal | 307 | 79.0 | 70.8 | 23,062 |
| extrapyramidal disorderSignal | 302 | 42.3 | 37.8 | 11,996 |
| electrocardiogram qt prolongedSignal | 283 | 27.2 | 24.3 | 7,082 |
| leukopeniaSignal | 316 | 21.8 | 19.6 | 6,236 |
| suicide attemptSignal | 282 | 16.0 | 14.3 | 3,956 |
| drug abuseSignal | 261 | 10.8 | 9.6 | 2,313 |
| drug interactionSignal | 483 | 10.5 | 9.6 | 4,155 |
| neutropeniaSignal | 408 | 10.3 | 9.4 | 3,443 |
| toxicity to various agentsSignal | 416 | 8.5 | 7.7 | 2,758 |
| weight increasedSignal | 446 | 6.9 | 6.3 | 2,243 |
| confusional stateSignal | 247 | 5.3 | 4.7 | 853 |
| somnolenceSignal | 280 | 4.8 | 4.3 | 841 |
| drug ineffectiveSignal | 872 | 2.3 | 2.1 | 662 |
| off label use | 333 | 1.3 | 1.2 | 25 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.